What Estratest treats: main uses and benefits

Estratest (esterified estrogens and methyltestosterone) is applied in addressing symptom clusters that may become intense or disruptive during the menopausal transition, often used during phases when symptoms become more noticeable. This combination therapy is considered relevant across domains where additional symptomatic support is needed in situations involving episodic or fluctuating manifestations.

The primary therapeutic area involves supportive management for moderate to severe vasomotor symptoms associated with menopause. These symptoms are related to systemic imbalance and include symptoms related to physical discomfort and heightened physiological activity. The medication is commonly used when short-term symptomatic assistance is needed in clinical settings that involve acute or unstable symptom patterns.

The medicine contributes to improved comfort during periods of heightened symptoms, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations. This supportive relief assists with maintaining functional stability when symptoms interfere with routine activities.

“The supportive nature of this assistance may help ease the overall symptom burden associated with episodes of heightened discomfort.”

Quick Fact: Relevant for Managing Vasomotor Symptoms

Regulatory References

1. DailyMed - NIH

Estratest (esterified estrogens and methyltestosterone) is not appropriate for all patients and is contraindicated (must not be used) in several specific situations, as defined by regulatory labeling.

Populations for whom use is Contraindicated

The medicine is strictly prohibited for women with:

• Known, suspected, or history of breast cancer or any estrogen-dependent neoplasia.
• Active or a history of blood clotting disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or myocardial infarction (MI).
• Liver dysfunction or disease (including severe liver damage).
• Undiagnosed abnormal genital bleeding.
• Known or suspected pregnancy, as use may cause severe harm to the fetus.
• Breast-feeding mothers, due to the possibility of masculinization of the nursing infant.
• Known hypersensitivity to any of its ingredients.

Restricted or Not Recommended Use

Use of this combination medicine is not recommended in pediatric patients (children). Patients with compromised cardiac reserve or renal disease require special consideration and close monitoring due to the risk of fluid retention. While appropriate studies do not limit its use in the elderly, geriatric patients may require caution and dose adjustment due to a higher likelihood of age-related heart, liver, or kidney issues.

Interactions with other medicines and products

Interaction Scope and Classification

The official interaction profile for Estratest is defined by both pharmacokinetic (PK) and pharmacodynamic (PD) changes that affect drug exposure and physiological function. The most stringent restriction is the functional contraindication against co-administration with Aromatase Inhibitors (e.g., Anastrozole, Exemestane), which is documented to directly oppose the intended hormonal replacement by negating the effect of the inhibitor.

Official Regulatory Statements

Regulatory documents state that co-administration with hepatic enzyme inducers, such as Rifampin and Phenytoin, may enhance metabolic clearance, leading to reduced plasma exposure of Esterified Estrogens. Conversely, substances like Grapefruit Juice and certain azole antifungals may increase estrogen concentrations through metabolic inhibition. The effects of the two active components are documented to interact with Oral Anticoagulants (e.g., Warfarin), where the combination may result in an altered anticoagulant response requiring monitoring. The androgen component is also documented to interact with Antidiabetic Agents, noting the potential for decreased insulin requirements. The label specifies that the risk of serious cardiovascular events is greater when the drug is combined with Tobacco/Cigarette Smoking, especially in women over 35 years of age.

The drug Estratest is a combination of esterified estrogens and methyltestosterone, which exert their effects by interacting with their cognate nuclear receptors in responsive tissues. The esterified estrogens component functions primarily as an agonist at the estrogen receptor (ER). Upon binding, the activated ER complex translocates into the cell nucleus, where it modulates gene transcription by binding to estrogen response elements (EREs) on DNA. This action regulates the synthesis of various proteins and peptides, resulting in the physiological modulation associated with estrogenic compounds. Simultaneously, methyltestosterone, a synthetic androgen, acts as an agonist at the androgen receptor (AR). The activated AR complex also translocates to the nucleus, binding to androgen response elements (AREs) to modulate the transcription of androgen-responsive genes. The combined action of these two hormonal components allows for the simultaneous modulation of both the estrogenic and androgenic signaling pathways within target cells.

General Administration and Dosage Principles

Estratest is administered exclusively by the oral route as a tablet. The medication is available in two standardized strengths: Full Strength (F.S.) and Half Strength (H.S.). The F.S. tablet contains 1.25 mg of Esterified Estrogens and 2.5 mg of Methyltestosterone.

The official instruction is to utilize the lowest effective dose to achieve therapeutic results. The typical adult dosing regimen involves taking one tablet daily of the F.S. strength, or one to two tablets daily of the H.S. strength. The medication may be taken with or without food.

Frequency and Duration of Use

Administration is structured around a cyclic pattern for short-term use only. This pattern typically involves taking the tablet for three consecutive weeks followed by a one-week medication-free interval, after which the cycle is resumed. Guidelines emphasize that the overall duration of use must be the shortest possible.

Treatment must be periodically reviewed, generally every three to six months, to assess the continued necessity of therapy, and attempts to discontinue the medication should be made at these intervals. The use of this combination product is not recommended in pediatric patients.

Handling Missed Doses

If a scheduled dose is missed, it should be taken as soon as the lapse is remembered. However, if the time is near for the next scheduled dose, the official instruction is to skip the missed dose and resume the regular sequence. It is specifically directed that patients do not take double or extra doses to compensate for a missed dose.

Research Evidence / Overview of Studies for Estratest

Evidence for Use in Moderate to Severe Vasomotor Symptoms

Research examining the estrogen and methyltestosterone combination has primarily centered on women experiencing moderate to severe vasomotor symptoms (VMS), such as hot flashes, that are associated with menopause. Studies have been conducted during periods of increased symptom activity and used in research contexts involving fluctuating or unstable symptoms. The evidence is derived mostly from short-term randomized controlled trials (RCTs). These studies were designed to compare the medicine with taking estrogen alone or with a placebo. This section summarizes evidence that contributes to understanding symptom patterns in the studied population.

The research focused on measuring outcomes related to physical discomfort and episodic changes by tracking the mean change in the frequency and severity of VMS. The specific populations studied were women whose symptoms did not experience sufficient relief after a period of treatment with estrogen alone. Findings describe patterns observed in the studies over the short follow-up period, and studies report how symptoms evolved in the observed populations.

Evidence for Loss of Sexual Interest or Desire

The combination medicine was also evaluated in research exploring whether it was associated with changes in loss of sexual interest or desire, often described as hypoactive sexual desire (HSD), in postmenopausal women. Studies explored this area using short-term, comparative trials that examined the combination therapy relative to treatment with estrogen alone. Research examined patient-reported outcomes describing perceived discomfort and changes in functional scores related to sexual desire, as well as shifts in specific endocrine biomarkers.

Research describes changes measured during the short study period (typically 8 to 10 weeks). Studies reported how symptoms evolved in the observed populations, and evidence suggests patterns related to changes in certain hormonal markers. However, the patterns related to self-reported sexual desire scores were variable across studies, depending on the specific measurement tools used within the trials. This evidence contributes to the broader evidence landscape but research does not determine whether an individual will respond similarly.

Key Research Gaps and Uncertainties

Due to the short duration of the primary efficacy trials (typically 8 to 12 weeks), long-term outcomes are not fully established. Information for long-term outcomes, such as long-term symptom patterns or how observed responses were maintained over many years, is limited within the specific clinical trial record for this combination. Furthermore, the specialized focus of the trials—such as studies focused on surgically menopausal women—means that the results apply only to the populations studied, and comparative evidence remains limited for many other patient groups.

Key Studies & References

1. Estratest (esterified estrogens and methyltestosterone tablets) Official Prescribing Information and Regulatory Label

Estratest (esterified estrogens and methyltestosterone) must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). Storage is permitted for brief periods during temperature excursions between 15°C and 30°C (59°F and 86°F).

Storage Requirements

Disposal Instructions

Unused or expired Estratest should not be flushed down a toilet or poured into a drain. To dispose of the product properly, follow local guidelines for medication disposal, such as those provided by a drug take-back program. This ensures safe and appropriate handling of the medication.